Cargando…
Frontiers in Clinical Drug Research. Volume 4, Diabetes and Obesity
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Sharjah :
Bentham Science Publishers,
2019.
|
| Colección: | Frontiers in Clinical Drug Research - Diabetes and Obesity Ser.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover; Title; Biblography; End User License Agreement; Contents; Preface; List of Contributors; Pharmacologic Obesity Treatment
- Emphasis on Efficacy and Cardiometabolic Markers; Fariha Salman1, Ivan Gerling2 and Helmut O. Steinberg*, 2; INTRODUCTION; Weight-Loss Drug Decreasing Food Absorption; Weight-Loss Drugs Decreasing Food Intake; Combination of Topiramate and Phentermine; Combination of Naltrexone and Bupropion; Liraglutide; Summary; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES
- Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic ComplicationsJessica Felton1 and Jean-Pierre Raufman2,*; INTRODUCTION AND OVERVIEW; Bile Acid Synthesis & Circulation; Bile Acid Feedback Mechanisms; TAKEDA G PROTEIN-COUPLED RECEPTOR-5 (TGR5); TGR5 & Immunity; TGR5 in the Liver and Gallbladder; TGR5 & Thyroid Hormone Activation; GLUCAGON-LIKE PEPTIDE 1 (GLP-1); Physiology of GLP-1; Effects of GLP-1; Pathophysiology of GLP-1; THE ROLE OF TGR5 IN GLP-1 SECRETION; THE ROLE OF FXR IN GLUCOSE HOMEOSTASIS
- MANIPULATING THE BILE ACID POOL FOR GLUCOSE HOMEOSTASISBILE ACIDS & GLP-1 AFTER BARIATRIC SURGERY; Glucose Homeostasis following Gastric Bypass Surgery; Increased Bile Acid Levels after Gastric Bypass Surgery; PHARMACOLOGY; GLP-1 Agonists; DPP4 Inhibitors; TGR5 Agonists; FUTURE DIRECTIONS; CONCLUSIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Sodium-Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus: The 'New Kids on the Block' in the Era of Evidence-based Medicine; Cheow Peng Ooi1,*, Norlaila Mustafa2, Nor Azmi Kamaruddin2 and Munn Sann Lye3
- INTRODUCTIONEpidemiology; Pathophysiology of T2DM; Glycaemic Control; NEW TREATMENT OPTION; Role of SGLTs in Glucose Homoeostasis; Drug Development Status of SGLT Inhibitors; Efficacy of SGLT2 Inhibitors; Safety of SGLT2 Inhibitors; Post-regulatory Approval and Long-term Safety Concerns; EVIDENCE-BASED MEDICINE; Evidence-based Medicine at the Crossroads; Dilemmas in Evidence-based Medicine; Restricted View of Evidence; Limitations of Clinical Trials; Misleading Results; Issues in Translating RCTs to the Clinical Care Arena; The Efficacy-Efficiency Gap; Secondary Research of Evidence Synthesis